Abstract
The relationship of the neutralizing activity (NA) profile of sera from human immunodeficiency virus (HIV)-infected individuals to the HIV viral load and the absolute CD4 count was examined. The NA of 24 serum samples against autologous isolates (AI) and HIV type 1 strain MN was examined. Three NA patterns were recognized. Nine sera neutralized both AI and MN (+/+), six sera neutralized MN but not AI (-/+), and nine sera failed to neutralize both AI and MN (-/-). The identification of the three neutralization patterns (+/+, -/+, and -/-) indicated that resistance to neutralization was progressive. A reciprocal relationship between the viral burden of the patients and the NA profiles was observed. The nine subjects with a -/- NA profile had a plasma viral load of ≥5 x 104 copies/ml and a cellular viral burden of ≥1,122 infectious units per million viable cells, which were significantly different from those of the other groups (P < 0.02). These patterns were independent of the phenotypic characteristics of the virus. Longitudinally, subjects with a -/- profile at baseline gained their HIV- specific NA by 24 weeks of antiretroviral therapy when this was associated with a ≥1-log10 decline in the plasma HIV viral load. The sera from week 24 from some patients were able to neutralize both the 24-week and the baseline dominant virus isolates. A change in CD4 cell count of 50 or more in either direction predicted a -/- or +/+ profile. The verification of the autologous NA profile might be important in selecting patients who may benefit from immune-based therapies involving neutralizing monoclonal antibodies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 412-416 |
| Number of pages | 5 |
| Journal | Clinical and Diagnostic Laboratory Immunology |
| Volume | 7 |
| Issue number | 3 |
| DOIs | |
| State | Published - May 2000 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Microbiology (medical)
- Immunology and Allergy
- Clinical Biochemistry
- Immunology
Cite this
Neutralization profiles of sera from human immunodeficiency virus (HIV)- infected individuals : Relationship to HIV viral load and CD4 cell count. / Nokta, Mostafa; Turk, Patricia; Loesch, Kimberly; Pollard, Richard B.
In: Clinical and Diagnostic Laboratory Immunology, Vol. 7, No. 3, 05.2000, p. 412-416.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Neutralization profiles of sera from human immunodeficiency virus (HIV)- infected individuals
T2 - Relationship to HIV viral load and CD4 cell count
AU - Nokta, Mostafa
AU - Turk, Patricia
AU - Loesch, Kimberly
AU - Pollard, Richard B
PY - 2000/5
Y1 - 2000/5
N2 - The relationship of the neutralizing activity (NA) profile of sera from human immunodeficiency virus (HIV)-infected individuals to the HIV viral load and the absolute CD4 count was examined. The NA of 24 serum samples against autologous isolates (AI) and HIV type 1 strain MN was examined. Three NA patterns were recognized. Nine sera neutralized both AI and MN (+/+), six sera neutralized MN but not AI (-/+), and nine sera failed to neutralize both AI and MN (-/-). The identification of the three neutralization patterns (+/+, -/+, and -/-) indicated that resistance to neutralization was progressive. A reciprocal relationship between the viral burden of the patients and the NA profiles was observed. The nine subjects with a -/- NA profile had a plasma viral load of ≥5 x 104 copies/ml and a cellular viral burden of ≥1,122 infectious units per million viable cells, which were significantly different from those of the other groups (P < 0.02). These patterns were independent of the phenotypic characteristics of the virus. Longitudinally, subjects with a -/- profile at baseline gained their HIV- specific NA by 24 weeks of antiretroviral therapy when this was associated with a ≥1-log10 decline in the plasma HIV viral load. The sera from week 24 from some patients were able to neutralize both the 24-week and the baseline dominant virus isolates. A change in CD4 cell count of 50 or more in either direction predicted a -/- or +/+ profile. The verification of the autologous NA profile might be important in selecting patients who may benefit from immune-based therapies involving neutralizing monoclonal antibodies.
AB - The relationship of the neutralizing activity (NA) profile of sera from human immunodeficiency virus (HIV)-infected individuals to the HIV viral load and the absolute CD4 count was examined. The NA of 24 serum samples against autologous isolates (AI) and HIV type 1 strain MN was examined. Three NA patterns were recognized. Nine sera neutralized both AI and MN (+/+), six sera neutralized MN but not AI (-/+), and nine sera failed to neutralize both AI and MN (-/-). The identification of the three neutralization patterns (+/+, -/+, and -/-) indicated that resistance to neutralization was progressive. A reciprocal relationship between the viral burden of the patients and the NA profiles was observed. The nine subjects with a -/- NA profile had a plasma viral load of ≥5 x 104 copies/ml and a cellular viral burden of ≥1,122 infectious units per million viable cells, which were significantly different from those of the other groups (P < 0.02). These patterns were independent of the phenotypic characteristics of the virus. Longitudinally, subjects with a -/- profile at baseline gained their HIV- specific NA by 24 weeks of antiretroviral therapy when this was associated with a ≥1-log10 decline in the plasma HIV viral load. The sera from week 24 from some patients were able to neutralize both the 24-week and the baseline dominant virus isolates. A change in CD4 cell count of 50 or more in either direction predicted a -/- or +/+ profile. The verification of the autologous NA profile might be important in selecting patients who may benefit from immune-based therapies involving neutralizing monoclonal antibodies.
UR - http://www.scopus.com/inward/record.url?scp=0034019766&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034019766&partnerID=8YFLogxK
U2 - 10.1128/CDLI.7.3.412-416.2000
DO - 10.1128/CDLI.7.3.412-416.2000
M3 - Article
C2 - 10799454
AN - SCOPUS:0034019766
VL - 7
SP - 412
EP - 416
JO - Clinical and Vaccine Immunology
JF - Clinical and Vaccine Immunology
SN - 1556-6811
IS - 3
ER -